New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Leerink raised its price target yesterday for shares of Alkermes to $66 after the company reported positive top-line aripiprazole lauroxil Phase III data. The firm expects FDA approval and launch in Q3 of 2015 and reiterates an Outperform rating on the stock.
News For ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
06:14 EDTALKSAlkermes price target raised to $72 from $60 at Citigroup
Subscribe for More Information
December 15, 2014
07:02 EDTALKSAlkermes announces initiation of Phase 1 aripiprazole lauroxil study
Subscribe for More Information
December 8, 2014
08:50 EDTALKSAlkermes price target raised to $63 on pipeline catalysts at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use